JP7610410B2 - 副甲状腺ホルモンアナログの経口製剤および治療 - Google Patents

副甲状腺ホルモンアナログの経口製剤および治療 Download PDF

Info

Publication number
JP7610410B2
JP7610410B2 JP2020564221A JP2020564221A JP7610410B2 JP 7610410 B2 JP7610410 B2 JP 7610410B2 JP 2020564221 A JP2020564221 A JP 2020564221A JP 2020564221 A JP2020564221 A JP 2020564221A JP 7610410 B2 JP7610410 B2 JP 7610410B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
containing compound
oral pharmaceutical
metal
chromium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522550A5 (https=
JP2022522550A (ja
Inventor
ジーグフリート グシュリエッサー
ブシャン ドゥルブクマール デサイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2022522550A publication Critical patent/JP2022522550A/ja
Priority to JP2024165292A priority Critical patent/JP2024178360A/ja
Publication of JP2022522550A5 publication Critical patent/JP2022522550A5/ja
Application granted granted Critical
Publication of JP7610410B2 publication Critical patent/JP7610410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020564221A 2019-03-08 2020-03-06 副甲状腺ホルモンアナログの経口製剤および治療 Active JP7610410B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024165292A JP2024178360A (ja) 2019-03-08 2024-09-24 副甲状腺ホルモンアナログの経口製剤および治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921009082 2019-03-08
IN201921009082 2019-03-08
PCT/IB2020/051958 WO2020183318A1 (en) 2019-03-08 2020-03-06 Oral formulation and treatment of pth analog.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024165292A Division JP2024178360A (ja) 2019-03-08 2024-09-24 副甲状腺ホルモンアナログの経口製剤および治療

Publications (3)

Publication Number Publication Date
JP2022522550A JP2022522550A (ja) 2022-04-20
JP2022522550A5 JP2022522550A5 (https=) 2024-10-28
JP7610410B2 true JP7610410B2 (ja) 2025-01-08

Family

ID=72426161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564221A Active JP7610410B2 (ja) 2019-03-08 2020-03-06 副甲状腺ホルモンアナログの経口製剤および治療
JP2024165292A Pending JP2024178360A (ja) 2019-03-08 2024-09-24 副甲状腺ホルモンアナログの経口製剤および治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024165292A Pending JP2024178360A (ja) 2019-03-08 2024-09-24 副甲状腺ホルモンアナログの経口製剤および治療

Country Status (6)

Country Link
US (1) US20220133857A1 (https=)
JP (2) JP7610410B2 (https=)
KR (1) KR20210137373A (https=)
CN (1) CN111971027A (https=)
TW (1) TWI821541B (https=)
WO (1) WO2020183318A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024178360A (ja) * 2019-03-08 2024-12-24 アニヤ バイオファーム インク． 副甲状腺ホルモンアナログの経口製剤および治療

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
KR102844771B1 (ko) * 2022-07-22 2025-08-12 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법
WO2025037993A1 (en) 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519867A (ja) 2003-03-04 2006-08-31 アユールベデイツク−ライフ・インターナシヨナル・エルエルシー 治療用組成物
JP2017531665A (ja) 2014-10-07 2017-10-26 シプルメット・ゲーエムベーハー ペプチド又はタンパク質薬物を経口送達するための医薬製剤
JP2018504444A (ja) 2015-02-09 2018-02-15 エンテラ バイオ エルティーディー． 骨粗鬆症の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US20040121025A1 (en) * 2002-12-20 2004-06-24 Mckee Dwight Oral composition for the treatment and prevention of bone loss
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
JP5324781B2 (ja) * 2004-06-14 2013-10-23 ビーエーエスエフ、ビューティー、ケア、ソルーションズ、フランス、エスエーエス Ｐｔｈ断片含有化粧品
JP5740689B2 (ja) * 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
EP3016674A4 (en) * 2013-06-23 2017-03-15 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
JP2018529749A (ja) * 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519867A (ja) 2003-03-04 2006-08-31 アユールベデイツク−ライフ・インターナシヨナル・エルエルシー 治療用組成物
JP2017531665A (ja) 2014-10-07 2017-10-26 シプルメット・ゲーエムベーハー ペプチド又はタンパク質薬物を経口送達するための医薬製剤
JP2018504444A (ja) 2015-02-09 2018-02-15 エンテラ バイオ エルティーディー． 骨粗鬆症の治療

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024178360A (ja) * 2019-03-08 2024-12-24 アニヤ バイオファーム インク． 副甲状腺ホルモンアナログの経口製剤および治療

Also Published As

Publication number Publication date
TWI821541B (zh) 2023-11-11
TW202100182A (zh) 2021-01-01
US20220133857A1 (en) 2022-05-05
JP2024178360A (ja) 2024-12-24
KR20210137373A (ko) 2021-11-17
CN111971027A (zh) 2020-11-20
JP2022522550A (ja) 2022-04-20
WO2020183318A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
JP7610410B2 (ja) 副甲状腺ホルモンアナログの経口製剤および治療
KR100498646B1 (ko) 경구용 펩티드 약학적 조성물
CN101801309B (zh) 口服递送的肽药物
JP2010184945A (ja) 経口ペプチド医薬投与形および製造方法
US20170304195A1 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
US12208118B2 (en) Pharmaceutical compositions for delivery of peptide
JP2018529749A5 (https=)
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
EP3244878B1 (en) Solid oral dosage forms
KR100679677B1 (ko) 생물학적 활성제의 점막흡수 증강을 위한 전달제
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
CN1809377B (zh) 包含微粉化形式的传送剂的口服给药药物组合物
JP2024523580A (ja) 肝疾患治療の組合せ療法
EP2964193B1 (en) Pharmaceuticals for oral delivery
JP5892940B2 (ja) クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
JP3628713B2 (ja) 生理学的に活性なペプチドを含有する膣投与製剤
EP4026566B1 (en) Oral pharmaceutical composition comprising teriparatide and method for preparing same
US20170189363A1 (en) Gastric acid modulators for oral delivery of peptides and proteins
WO2025250813A1 (en) Use of radionuclide pp-f11n in a chemotherapy like fast injection cycles
HK40104848A (zh) 肝病治疗的组合疗法
HK1216082B (zh) 口服遞送的藥物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240924

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241220

R150 Certificate of patent or registration of utility model

Ref document number: 7610410

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150